Are These Stocks On A Direct Course For Rock Bottom? RadioShack Corporation(NYSE:RSH), Orexigen Therapeutics, Inc.(NASDAQ:OREX), and Rock Creek Pharmaceuticals Inc(NASDAQ:RCPI)

Posted by Saimoon August 5, 2014 0 Comment 1557 views


New York, NY – 08/5/2014 –  HotStockGains provides investors  and traders with valuable trading strategies via text message and email. To join our free text message alerts service just text the word BREAKOUT to 555888 from your cell phone. Just text STOP to unsubscribe if you ever need to.

RadioShack Corporation(NYSE:RSH) suffered a three cent loss during yesterday’s trading, a 5.38% decrease in value that moved the stock to a closing price of $0.55. However, the Texas-based consumer electronics company did regain two cents in after-hours trading to move to a value of $0.57. Nevertheless, yesterday’s closing price does represent a new 52 week low for the company that was once a go-to option for consumers. On July 29th, Moody’s announced that RadioShack may run out of cash by Oct. 2015.

Will RadioShack Rebound From Its Recent Losses? Take A Look At Our Free RSH Analysis.

Orexigen Therapeutics, Inc.(NASDAQ:OREX) enjoyed a 0.40% increase in value during yesterday’s trading, gaining two cents to close at $4.99. Unlike RadioShack, however, Orexigen did not fare well in after-hours trading, as the stock lost seven cents to move to a $4.92. The new value places California-based biopharmaceutical company, which develops product candidates for the treatment of obesity, just $0.39 above its 52 week low of $4.60. Orexigen Therapeutics will host a second quarter 2014 financial results conference call on August 7th, 2014.

Should You Sell Your Shares Before Orexigen Therapeutics Reveals Its Financial Results? View Our Free OREX Analysis.

Rock Creek Pharmaceuticals Inc(NASDAQ:RCPI) fell eleven cents during yesterday’s trading to move to a closing price value of $0.30. The mark represents a new 52 week low for the pharmaceutical company. Rock Creek, a company which develops products targeting inflammatory and neurological disorders, announced yesterday that it would be presenting at the BioPharm America 2014 conference to be held on Sept. 22-24. At the conference, CEO Michael Mullan will present data on anatabine citrate as well as the company’s strategy for the molecule’s phase I and phase II studies.

Where Will Rock Creek Pharmaceutical’s Value Be When Mullan Makes His Presentation? Receive A Free RCPI Analysis.

About HotStockGains

I have a confession to make – I am not always right. Sometimes, unfortunately, I will send alerts that experience losses.

I have alerted companies that rallied 100% or even 6,000% (not even joking) in under a week. Likewise, I have alerted companies that tanked 10, 20, sometimes even as much as 30 or 40%. However overall it is about the net result that delivers profits into your portfolio.

Sign up for my free newsletter to receive market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks. If you are not satisfied, simply click unsubscribe.

Disclosure:  HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://hotstockgains.com/disclaimer/ for complete risks and disclosures.


Write Your Comment